Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 1, 2014, Pages 20-31

  Staeker, Julia ^a   Leucht, Stefan ^b   Laika, Barbara ^a   Steimer, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DULOXETINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; REBOXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGED; ALLELE; ANOREXIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; ELECTROPHORESIS; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HOSPITALIZATION; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; NEUROMUSCULAR DISEASE; PARANOIA; PHARMACOGENETICS; REAL TIME POLYMERASE CHAIN REACTION; SELF CONCEPT; SEROTONINERGIC SYSTEM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VARIABLE NUMBER OF TANDEM REPEAT; VERY ELDERLY; YOUNG ADULT;

ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; INPATIENTS; MALE; POLYMORPHISM, GENETIC; SEROTONIN; TREATMENT OUTCOME;

EID: 84891855913     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0217     Document Type: Article

References (56)

1. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312.
2. Baffa A, Hohoff C, Baune BT, et al. (2010) Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 62:121-131.
3. Dogan O, Yuksel N, Ergun MA, et al. (2008) Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 12:225-231.
4. Fiskerstrand CE, Lovejoy EA, Quinn JP (1999) An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458:171-174.
5. Frazer A (1997) Pharmacology of antidepressants. J Clin Psychopharmacol 17 Suppl 1:2S-18S.
6. Gao K, Kemp DE, Fein E, et al. (2011) Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 72:1063-1071.
7. Gray JA, Roth BL (2001) Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441-451.
8. Guy W (1976a) Clinical Global Impression Scale. U.S. Department of Health, Education and Human Welfare publication (ADM), Washington DC.
9. Guy W (1976b) Dosage record and Treatment Emergent Symptoms Scale. U.S. Department of Health, Education and Human Welfare publication (ADM), Washington DC.
10. Horstmann S, Lucae S, Menke A, et al. (2008) Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients. Eur Neuropsychopharmacol 18:S214-S215.
11. Horstmann S, Lucae S, Menke A, et al. (2010) Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35:727-740.
12. Hu XZ, Lipsky RH, Zhu G, et al. (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessivecompulsive disorder. Am J Hum Genet 78:815-826.
13. Hu XZ, Rush AJ, Charney D, et al. (2007) Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64:783-792.
14. Kim DK, Lim SW, Lee S, et al. (2000) Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11: 215-219.
15. Kishi T, Yoshimura R, Kitajima T, et al. (2010) HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med 12:237-242.
16. Kraft JB, Slager SL, McGrath PJ, et al. (2005) Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58:374-381.
17. Laika B (2009) Pharmacogenetic screening of psychiatric inpatients: associations between clinical outcome and selected polymorphisms in drug metabolism, drug transport and drug target structures. In: WZW, Lehrstuhl fu r Experimentelle Genetik. TU Mu nchen, Mu nchen, Germany.
18. Laika B, Leucht S, Heres S, et al. (2009) Pharmacogenetics and olanzapine treatment: CYP1A2 1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 10:20-29.
19. Laje G, Cannon DM, Allen AS, et al. (2010) Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol 13:715-724.
20. Lee SH, Choi TK, Lee E, et al. (2010) Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology 62:198-206.
21. Lesch KP, Balling U, Gross J, et al. (1994) Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 95:157-162.
22. Leysen JE (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11-26.
23. Lovejoy EA, Scott AC, Fiskerstrand CE, et al. (2003) The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur J Neurosci 17:417-420.
24. MacKenzie A, Quinn J (1999) A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A 96: 15251-15255.
25. Maron E, Tammiste A, Kallassalu K, et al. (2009) Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 19:451-456.
26. McMahon FJ, Buervenich S, Charney D, et al. (2006) Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804-814.
27. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106S-115S.
28. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D- 1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
29. Min W, Li T, Ma X, et al. (2009) Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 205:409-417.
30. Mrazek DA, Rush AJ, Biernacka JM, et al. (2009) SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 150B:341-351.
31. Mundo E, Walker M, Cate T, et al. (2001) The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 58:539-544.
32. Murphy GM, Jr., Hollander SB, Rodrigues HE, et al. (2004) Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61:1163-1169.
33. Newton RA, Elliott JM (1997) Mianserin-induced downregulation of human 5-hydroxytryptamine2A and 5- hydroxytryptamine2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y. J Neurochem 69: 1031-1038.
34. Ng CH, Easteal S, Tan S, et al. (2006) Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 30:953-957.
35. Parsey RV, Hastings RS, Oquendo MA, et al. (2006) Effect of a triallelic functional polymorphism of the serotonin-transporter- linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 163:48-51.
36. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21:123-139.
37. Perlis RH, Mischoulon D, Smoller JW, et al. (2003) Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54:879-883.
38. Peters EJ, Slager SL, Jenkins GD, et al. (2009) Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 19:1-10.
39. Popp J (2006) Methodische und klinische Untersuchungen zur Pharmakogenetik der Psychopharmakotherapie. TU Mu nchen, Mu nchen, Germany.
40. Popp J, Leucht S, Heres S, et al. (2006) Serotonin transporter polymorphisms and side effects in antidepressant therapy-A pilot study. Pharmacogenomics 7:159-166.
41. Popp J, Leucht S, Heres S, et al. (2010) Corrigendum to Serotonin transporter polymorphisms and side effects in antidepressant therapy-A pilot study. Pharmacogenomics 11:1504.
42. Porcelli S, Drago A, Fabbri C, et al. (2011) Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 36:87-113.
43. Porcelli S, Fabbri C, Serretti A (2012) Meta-Analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22:239-258.
44. Praschak-Rieder N, Kennedy J, Wilson AA, et al. (2007) Novel 5- HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry 62:327-331.
45. Quirion R, Richard J, Dam TV (1985) Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex. Brain Res 333:345-349.
46. Smits K, Smits L, Peeters F, et al. (2007) Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 22:137-143.
47. Stein MB, Seedat S, Gelernter J (2006) Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187: 68-72.
48. Takahashi H, Yoshida K, Ito K, et al. (2002) No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 12:477-481.
49. Takano H, Ito H, Takahashi H, et al. (2011) Serotonergic neurotransmission in the living human brain: a positron emission tomography study using [(1)(1)C]dasb and [(1)(1)C]WAY100635 in young healthy men. Synapse 65:624-633.
50. Tanaka M, Kobayashi D, Murakami Y, et al. (2008) Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 11:261-267.
51. Taylor DP, Carter RB, Eison AS, et al. (1995) Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 56 Suppl 6:3-11.
52. Tollefson GD, Sanger TM, Lu Y, et al. (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250-258.
53. Uher R, Huezo-Diaz P, Perroud N, et al. (2009) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9:225-233.
54. World Health Organization (2010) Anatomical Therapeutic Chemical (ATC) Index 2010 Including Defined Daily Doses (DDD), www.whocc.no/atc-ddd-index
55. Yamauchi M, Miyara T, Matsushima T, et al. (2006) Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 1067:164-169.
56. Zerssen D (1976) Paranoid-Depressivita ts-Skala Selbstbeurteilungs- Skala (PD-S/D-S). Beltz, Go ttingen.